 Even as many big drug makers abandon a oncehot gene technology a small pocket of companies is doubling down on it convinced the approach still has promise The technology seeks to disable molecules called ribonucleic acids or RNA from translating genetic code into diseasecausing proteins As recently as  nearly every large pharmaceutical company including Pfizer Inc and Merck  Co had research teams working on RNAtargeted therapies but technical challenges in delivering the drugs into human cells led
  